$STEM

STEM Shares Gains 12% on Narrower Q2 Loss, Revenues Increased Y/Y

STEM stock has risen nearly 12% after second-quarter revenue beat estimates, driven by strong growth in software and managed services.

Original reporting
Zacks Commentary · Zacks Investment Research
Published Aug 12, 2025, 3:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
STEM Shares Gains 12% on Narrower Q2 Loss, Revenues Increased Y/Y — source image
Decision brief

The 30-second read

$STEMBullishMed
01

Why it matters

The positive earnings and revenue growth have bolstered investor confidence, leading to a 12% stock increase and improved sector sentiment.

02

Market read

The news is highly relevant for traders focusing on technology and manufacturing stocks, especially those with exposure to STEM.

03

What to watch

Potential macroeconomic headwinds or sector rotation could dampen gains; also, high valuation levels warrant caution.

Timing: Immediate, as earnings report is recent and market reaction is ongoing.

Background

STEM reported a narrower Q2 loss and increased revenues, driven by growth in software and managed services segments.

Company-level read

Ticker impact

$STEMBullishHigh confidence
Context

Primary focus of the news, directly impacted by Q2 earnings report.

Expected impact

Moderate upward movement in near-term, potential for continued gains if earnings momentum persists.

Evidence & confidence

The stock's significant rise post-earnings suggests strong investor confidence and positive earnings surprises, supported by revenue growth in key segments.

Market effects

Potential positive sentiment boost for the technology and manufacturing sectors.

Limited regional impact, primarily affecting US-based tech stocks.

Moderate, as STEM operates in a global market, but impact is sector-specific.

Counterpoint

The stock's rise may be overextended; a correction could occur if future earnings disappoint or market sentiment shifts.

Key entities

  • STEM Inc.

    A provider of software and managed services in the technology sector.

Related articles

$STEMMed

Stem, Inc.: Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary

Stem, Inc. (NYSE: STEM) said Solarmarkt Group, with EPC partner Pannonwatt, selected Stem’s PowerTrack Energy Management System to hybridize two operating utility-scale solar plants in Hungary. The five-year agreement covers adding 40 MW/80 MWh batteries to each site, targeting commercial operation by Sept 2026 and participation in Hungary’s aFRR market.

$STEMMed

STEM, INC. (STEM): Completion of Acquisition or Disposition of Assets

STEM, INC. (STEM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99 Stem Announces Second Quarter 2026 Results Achieved fifth consecutive quarter of positive adjusted EBITDA PowerTrack TM software revenue up 11% YoY PowerTrack TM Energy Management System (EMS) recognized as leading, global innovative solution with The smarter E AWARD w

$PSKYMed

Why Did PSKY, UBER, STEM Stocks Plummet To 52-Week Lows?

Stocks of Paramount Skydance (PSKY), Uber (UBER) and Stem (STEM) hit 52-week lows. PSKY fell after delaying its Warner Bros. Discovery merger to June 1, 2027 amid a multistate antitrust suit. UBER dropped on slower growth and Waymo partnership concerns. STEM slid on EV charging weakness and Barclays cut its price target to $8; revenue fell 11% to $29M.

$NKTRMed

Nektar Therapeutics Wins $90M Lilly Verdict

A jury awarded Nektar Therapeutics $90M in damages after finding Eli Lilly breached a license agreement. Nektar said the verdict is subject to post-trial proceedings and appeals. The dispute involves a collaboration for developing rezpegaldesleukin. Nektar Therapeutics (NASDAQ:NKTR) and Eli Lilly (NYSE:LLY) are involved.